Antibody Drug Conjugates (ADCs) are fulfilling their promise as a new therapeutic class for the treatment of cancer.
But ADCs are complex multicomponent molecules presenting unique manufacturing challenges as it requires experience of both biological and small molecule manufacturing, combined with HPAPI handling and cGMP facilities.
As a drug innovator working in the ADC field, do you face challenges to develop and manufacture your ADC drug candidate?
With more than 15 years’ experience, Novasep offers a full and flexible range of CDMO services for ADCs.
Discover how we supported one of our clients with the development and cGMP manufacturing of its ADC for Phase I clinical trials in our latest case study!